MacroGenics, Inc. (NASDAQ:MGNX ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Jim Karrels - SVP and CFO Dr. Scott Koenig - President and CEO Conference Call Partici

Why MacroGenics Stock Blasted Higher Today

06:51pm, Friday, 04'th Nov 2022

A quarter that was far better than expected gets investors excited about the biotech at the end of the week.

MacroGenics (MGNX) Reports Q3 Loss, Tops Revenue Estimates

07:35pm, Thursday, 03'rd Nov 2022

MacroGenics (MGNX) delivered earnings and revenue surprises of 18.37% and 83.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics to Participate in Upcoming Investor Conferences

04:30pm, Wednesday, 02'nd Nov 2022

ROCKVILLE, MD, Nov. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for th

MacroGenics Announces Date of Third Quarter 2022 Financial Results Conference Call

04:30pm, Wednesday, 26'th Oct 2022

ROCKVILLE, MD, Oct. 26, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeu

Why MacroGenics Stock Sank Today

07:14pm, Monday, 12'th Sep 2022

An analyst had a fresh new take on the company's prospects, and it wasn't all that positive.

MacroGenics to Participate in Upcoming Investor Conferences

11:00am, Friday, 02'nd Sep 2022 GlobeNewswire Inc.

ROCKVILLE, MD, Sept. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for

MacroGenics to Participate in Upcoming Investor Conferences

07:00am, Friday, 02'nd Sep 2022

ROCKVILLE, MD, Sept. 02, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the

Where Macrogenics Stands With Analysts

01:36pm, Monday, 29'th Aug 2022 Benzinga

Over the past 3 months, 6 analysts have published their opinion on Macrogenics (NASDAQ:MGNX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a com

SVB Leerink Slashes Price Target On This Stock By Over 73%, Plus This Analyst Predicts $56 For Toll Brothers

11:54am, Monday, 29'th Aug 2022 Benzinga

Citigroup raised the price target for MacroGenics, Inc. (NASDAQ: MGNX) from $13 to $16. MacroGenics shares rose 4.8% to $3.90 in pre-market trading. Goldman Sachs raised the price target on JinkoSol

Wall Street Analysts Predict a 291% Upside in MacroGenics (MGNX): Here's What You Should Know

01:55pm, Friday, 12'th Aug 2022 Zacks Investment Research

The average of price targets set by Wall Street analysts indicates a potential upside of 291% in MacroGenics (MGNX). While the effectiveness of this highly sought-after metric is questionable, the pos

What 5 Analyst Ratings Have To Say About Macrogenics

08:08pm, Tuesday, 09'th Aug 2022 Benzinga

Macrogenics (NASDAQ:MGNX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 3 2 0 0 Last 30D

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by